Universal Omics

Universal Omics is a leading biotechnology research company dedicated to advancing healthcare through innovative solutions. Specializing in the in silico design of drugs and the analysis of bioactives, existing drugs, and nutraceuticals for cardiac disease and other metabolic impairments, Universal Omics is committed to repairing and regulating cell membranes to tackle global health challenges and enhance the quality of life. Located in Derio, Bizkaia at Astondo Bidea, 612 BIC BIZKAIA, Parke Tecnológico, Universal Omics leverages cutting-edge technology to address the growing unmet needs in the treatment of non-communicable diseases, particularly arrhythmia.

At Universal Omics, their mission is to provide innovative and personalized solutions that drive significant advancements in the treatment of non-communicable diseases, focusing on the absence of adverse effects in the medium and long term. The company’s core strength lies in its deep learning tool, DRUP-Drug Predictor, which offers a significant competitive advantage by enabling precise prediction of the efficacy of molecules under different conditions and doses. This streamlines the drug development process and ensures the safety and efficacy of end products.

Universal Omics continues to expand its capabilities, offering specialized services through the DRUP-Drug Predictor software, including high-throughput screening of biomolecules with anti-arrhythmic activity, analysis of the effectiveness of existing drugs and nutraceuticals, and the design or redesign of drugs and nutraceuticals. The company's management is actively working to complete further details about their pioneering work. We invite the manager of Universal Omics to create a customized and exclusive company showcase and product listing on our platform to further highlight their expertise and offerings.